Wockhardt
Wockhardt Limited, a prominent player in the global pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1960, the company has established a strong presence in key operational regions, including the United States, Europe, and emerging markets. Wockhardt is renowned for its innovative approach to healthcare, focusing on biotechnology, generics, and specialty pharmaceuticals.
The company’s core products encompass a diverse range of therapeutic areas, including antibiotics, vaccines, and biopharmaceuticals, distinguished by their commitment to quality and research-driven development. Wockhardt has achieved notable milestones, such as receiving multiple FDA approvals and expanding its manufacturing capabilities across the globe. With a robust market position, Wockhardt continues to contribute significantly to the healthcare landscape, driven by its dedication to improving patient outcomes and advancing medical science.
-1 vs industry average
Wockhardt’s score of 37 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Wockhardt?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Wockhardt's reported carbon emissions
In 2025, Wockhardt reported total carbon emissions of approximately 69,000,000 kg CO2e, comprising 8,738,840 kg CO2e from Scope 1, 61,310,660 kg CO2e from Scope 2, and 9,019,110 kg CO2e from Scope 3. This data reflects a commitment to transparency in emissions reporting, with a focus on both direct and indirect emissions. Wockhardt has set ambitious reduction targets, aiming for a 50% decrease in absolute emissions for both Scope 1 and Scope 2 by 2030, with the baseline year being 2021. This commitment underscores the company's proactive approach to climate action and aligns with industry standards for sustainability. The emissions data is not cascaded from any parent organization, indicating that Wockhardt Limited independently reports its carbon footprint. The company continues to enhance its environmental strategies, contributing to a more sustainable future in the pharmaceutical industry.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Wockhardt’s Climate Goals (2030 & 2050)
2 goals2030
50% reduction in Scope 1
aiming for a 50% decrease in absolute emissions by 2030
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 2 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Wockhardt
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project